Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Debiopharm and TCGLS Enter Into an Exclusive Research Agreement

Published: Tuesday, September 10, 2013
Last Updated: Tuesday, September 10, 2013
Bookmark and Share
Collaboration to develop a novel class of antibiotics, a new strategic therapeutic area for Debiopharm.

Debiopharm Group™ (Debiopharm) and TCG Lifesciences Limited (TCGLS) have announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections.
 
Debiopharm is willing to become a key player in the area of antibacterials to fulfill the increasing need of new classes of antibiotics to overcome resistance to current treatment.

Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimization of lead compounds whilst Debiopharm will provide drug development expertise and fund the development program.

“We foresee to increase our commitment in this field over next few months through additional partnerships and investments on other innovative targets” said David Deperthes, VP Business Development & Licensing.

"We are very enthusiastic about this partnership with TCGLS for the development of novel antibiotics, their extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio 1348. This partnership is key to us to establish a leadership position in the area of antibiotics” said Rolland-Yves Mauvernay, President and founder of Debiopharm Group™.

Swapan Bhattacharya, Managing Director of TCG Lifesciences commented: “We are indeed excited about this program which involves a challenging new target that could potentially address the vast incidence of nosocomial infections which plague healthcare facilities all over the world. Debiopharm’s developmental expertise combined with our medicinal chemistry capabilities and efficient discovery operations provide an attractive opportunity for accelerated discovery of novel drug candidates for clinical development.”

Antibiotic resistance and nosocomial infection
The CDC estimates that, each year, nearly 2 million people in the United States acquire an infection while in a hospital, resulting in 90,000 deaths.

More than 70 percent of the bacteria that cause these infections are resistant to at least one of the antibiotics commonly used to treat them.

In a report, the European CDC states that at least 25,000 patients in the EU die each year from infections due to bacteria that are resistant to a number of marketed drugs.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More Than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Debiopharm and EORTC Announce a Collaboration
Collaboration to investigate triptorelin for treatment of salivary gland cancers.
Thursday, January 14, 2016
EMA Grants Orphan Drug Designation to Debio 1143
Company grants EMA Designation to Debio 1143 for treatment of Ovarian Cancer.
Thursday, December 10, 2015
United and Debiopharm Announce the Launch of Pamorelin®
Pamorelin® one-, three- and six-month dosing option now available to patients in the Philippines.
Tuesday, December 08, 2015
Debiopharm’s Partner Yakult Announces Elplat® Approbation in Gastric Cancer
Approval for a supplemental new drug application for Elplat® in postoperative adjuvant chemotherapy in Japan.
Saturday, November 28, 2015
JCA and Debiopharm Group Announce Winners of the 2015 JCA-Mauvernay Award
The ‘JCA-Mauvernay Award 2015’ is awarded to Doctors Yutaka Kondo and Junko Takita.
Saturday, October 10, 2015
Debiopharm and Solid Biosciences Announces Collaboration
Debiopharm to start pre-clinical animal studies in Duchenne Muscular Dystrophy with Solid Biosciences.
Thursday, September 10, 2015
Debiopharm Acquires FibroTrap Sample Processing Technology from Spinomix
FibroTrap improves sensitivity and shortens time taken from sample collection to results.
Saturday, June 20, 2015
Debiopharm Announces Phase III Positive Results for Triptorelin 6-month Formulation
Triptorelin 6-month formulation phase III trial demonstrates good efficacy in terms of pituitary and gonadal suppression and in arresting or reversing progression of clinical signs of puberty and slowing down of accelerated bone maturation in children with CPP.
Friday, May 22, 2015
Debiopharm Initiates Clinical Phase II Study to Evaluate Debio 1450
One year after the initiation of Phase I, Debiopharm has announced the start of clinical phase II for Debio 1450 in ABSSSI and presentation of new data at ECCMID.
Friday, May 01, 2015
Debiopharm Announces Results of 2 Key Oncology Programs at AACR Conference
Company presents preclinical results for 2 anti-cancer targeted therapies Debio 1143 and Debio 1347.
Tuesday, April 21, 2015
Debiopharm Announces Progress in Phase I Single and Multiple Ascending Dose Study of Debio 1450
Debio 1450 - A highly potent anti-infective agent selectively active against Staphylococcus species.
Wednesday, October 15, 2014
Trelstar® Six-Month Dosing for Prostate Cancer Patients Launches in Canada
Trelstar® one-, three-, and six-month dosing options now available.
Wednesday, October 08, 2014
Orient EuroPharma and Debiopharm Group™ Announce Their Partnership
Both Companies also announces the launch of Pamorelin® LA in Singapore.
Tuesday, May 27, 2014
Debiopharm, Yale University Extend Collaboration
New license and research agreement regarding the discovery of MIF inhibitors.
Wednesday, May 07, 2014
Curis and Debiopharm Report Preclinical Data for Debio 0932
Debio 0932 demonstrated anti-tumor activity and synergy with various SOC agents in in vitro and xenograft models of NSCLC and RCC.
Wednesday, April 09, 2014
Scientific News
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Releasing Cancer Cells for Better Analysis
A new device developed at the University of Michigan could provide a non-invasive way to monitor the progress of an advanced cancer treatment.
Apricot Kernels Pose Risk of Cyanide Poisoning
Eating more than three small raw apricot kernels, or less than half of one large kernel, in a serving can exceed safe levels. Toddlers consuming even one small apricot kernel risk being over the safe level.
Cell Transplant Treats Parkinson’s in Mice
A University of Wisconsin—Madison neuroscientist has inserted a genetic switch into nerve cells so a patient can alter their activity by taking designer drugs that would not affect any other cell.
Understanding Female HIV Transmission
Glowing virus maps points of entry through entire female reproductive tract for first time.
Genetic Markers Influence Addiction
Differences in vulnerability to cocaine addiction and relapse linked to both inherited traits and epigenetics, U-M researchers find.
Lab-on-a-Chip for Detecting Glucose
By integrating microfluidic chips with fiber optic biosensors, researchers in China are creating ultrasensitive lab-on-a-chip devices to detect glucose levels.
A lncRNA Regulates Repair of DNA Breaks in Breast Cancer Cells
Findings give "new insight" into biology of tough-to-treat breast cancer.
COPD Linked to Increased Bacterial Invasion
Persistent inflammation in COPD may result from a defect in the immune system that allows airway bacteria to invade deeper into the lung.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!